Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating primary cancer which comprises administering to a patient in need of such treatment a therapeutically effective amount of ~~a topoisomerase inhibitor~~ topotecan, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, and a therapeutically effective amount of thalidomide, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof.

2. (Currently amended) A method of treating metastatic cancer which comprises administering to a patient in need of such treatment a therapeutically effective amount of ~~a topoisomerase inhibitor~~ topotecan, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, and a therapeutically effective amount of thalidomide, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof.

3. (Original) The method of claim 1 or 2 wherein the cancer is cancer of the head, neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, and brain.

4. (Original) The method of claim 3 wherein the cancer is colon or rectal cancer.

5-7. (Canceled).

8. (Currently amended) The method of claim ~~7~~ 1 or 2, wherein ~~the irinotecan or SN-38, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 1 to about 1000 mg/m^2, and~~ the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 1 to about 2000 mg.

9. (Currently amended) The method of claim 8 wherein ~~the irinotecan or SN-38, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 25 to about 750 mg/m^2, and~~ the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 1000 mg.

10. (Currently amended) The method of claim 9 wherein ~~the irinotecan or SN-38, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 500 mg/m^2, and~~ the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 100 to about 750 mg.

11. (Currently amended) The method of claim 10 wherein ~~the irinotecan or SN-38, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 100 to about 350 mg/m^2, and~~ the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 200 to about 500 mg.

12-60. (Canceled).

61. (Previously presented) The method of claim 1 or 2, wherein thalidomide is administered.

62. (Previously presented) The method of claim 1 or 2, wherein the thalidomide salt or solvate is administered.